Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 6OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 4399Urinary Bladder Neoplasms 1078Carcinoma, Renal Cell 1041Kidney Neoplasms 567Breast Neoplasms 453Neoplasms 403Carcinoma, Transitional Cell 299Neoplasm Metastasis 250Lung Neoplasms 242Testicular Neoplasms 202Melanoma 195Colorectal Neoplasms 193Ovarian Neoplasms 163Carcinoma, Non-Small-Cell Lung 150Sarcoma 135Non-Muscle Invasive Bladder Neoplasms 135Pancreatic Neoplasms 124Colonic Neoplasms 121Head and Neck Neoplasms 116Uterine Cervical Neoplasms 115Wilms Tumor 108Recurrence 106Motor Activity 100Stomach Neoplasms 89Urologic Neoplasms 88Neuroblastoma 88Disease 85Multiple Myeloma 83Carcinoma, Hepatocellular 79Adenocarcinoma 79

Interventions

enzalutamide 2sipuleucel-T 1Vancomycin 1Metronidazole 1Docetaxel 1Ciprofloxacin 1Amoxicillin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Metastatic Castration-Resistant Prostate Cancer (mCRPC) × Genitourinary × Clear all
NCT05806814 2026-05-27

OU-SCC-EXCITE

University of Oklahoma

Phase 1 Active not recruiting
15 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06126731 2025-11-24

Combination Study of Antibiotics With Enzalutamide (PROMIZE)

Institute of Cancer Research, United Kingdom

Phase 1/2 Recruiting
39 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT04015622 2025-08-20

PROTRACT

British Columbia Cancer Agency

Phase 2 Active not recruiting
100 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡